Clinical trial
Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously…
NCT00038571 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038571 |
|---|---|
| Title | Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy |
| Official title | Phase II Study of Proteasome Inhibitor PS-341 For Patients With Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, B-Cell |
| Intervention type | Drug |
| Interventions | PS341 (Bortezomib) |
| Enrollment | 60 |
| Start date | May 1, 2002 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Jun 3, 2002 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: